EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity

Sarah-Kim Friedrich-Becker, Michael Bergerhausen iD, Arshia Berry, Hilal Bhat, Fanghui Li, Rosa Schmitz iD, Lisa Holnsteiner iD, Dethardt Müller, Haifeng Xu, Philipp A Lang, Karl Sebastian Lang, Jörg Vollmer

Viruses · 2026

DOI: 10.3390/v18090998 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Sarah-Kim Friedrich-Becker und 11 weiteren Autor:innen. Beteiligte Einrichtung: Abalos Therapeutics GmbH, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Lymphocytic choriomeningitis virus, Mutation, Neoplasms, Viral Tropism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of effective viroimmunotherapies for cancer relies on the ability of replicating viruses to infect the entire tumor tissue and induce comprehensive inflammation within the tumor microenvironment (TME). In this study, we investigate the impact of mutations in the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV) on tumor cell infectivity, replication, and the immune response. Specifically, we focus on two key positions in GP1 (181 and 185) that significantly enhance tumor cell infectivity and improve CD8+ T cell function in the GP-mutated LCMV strain LCMV P52. Our findings demonstrate that LCMV strain LCMV P52 replicates preferentially in vivo in tumors, exhibits improved tumor penetration, attracts functional CD8+ T cells more effectively to the tumor, and reprograms the tumor toward a more immunogenic microenvironment to allow for effective checkpoint inhibitor combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytic choriomeningitis virusMutationNeoplasmsViral TropismAnimalsCD8-Positive T-LymphocytesTumor MicroenvironmentMiceHumansVirus ReplicationMice, Inbred C57BLCell Line, TumorOncolytic VirotherapyFemale

Stichwörter der Autor:innen

LCMVadaptive immunitycancercold tumorshot tumorsinnate immunitytumor microenvironmentviroimmunotherapy

Autor:innen und Institutionen

  • Abalos Therapeutics GmbH, 40225 Düsseldorf, Germany.
  • Institute of Immunology, University Hospital of Essen, 45147 Essen, Germany.
  • National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, 01309 Dresden, Germany.
  • Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University, 40225 Düsseldorf, Germany.

ORCID-Profile: Michael Bergerhausen, Rosa Schmitz, Lisa Holnsteiner

Zitieren

APA

Friedrich-Becker, S. K., Bergerhausen, M., Berry, A., Bhat, H., Li, F., Schmitz, R., Holnsteiner, L., Müller, D., Xu, H., Lang, P. A., Lang, K. S., & Vollmer, J. (2026). Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity. Viruses. https://doi.org/10.3390/v18090998

Vancouver

Friedrich-Becker SK, Bergerhausen M, Berry A, Bhat H, Li F, Schmitz R, et al. Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity. Viruses. 2026. doi:10.3390/v18090998

BibTeX
@article{FriedrichBecker2026,
  author = {Friedrich-Becker, Sarah-Kim and Bergerhausen, Michael and Berry, Arshia and Bhat, Hilal and Li, Fanghui and Schmitz, Rosa and Holnsteiner, Lisa and Müller, Dethardt and Xu, Haifeng and Lang, Philipp A and Lang, Karl Sebastian and Vollmer, Jörg},
  title = {Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity},
  journal = {Viruses},
  year = {2026},
  doi = {10.3390/v18090998}
}
Kostenlos starten →